finance.yahoo.com Earnings
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
Medical research ©rawpixel LeonaBio, Inc. (NASDAQ:LONA) reported a smaller-than-expected second-quarter loss on Monday as the clinical-stage biopharmaceutical company continued to advance its pivotal Phase 3 ELAINE-3 study of lasofoxifene. The company posted a loss of $0.80 per share for the quarter, outperforming analyst expectations for a loss of $1.12 per share. LeonaBio shares were unchanged in after-hours trading …